PV is in focus this spring. Join the #PolycythemiaVera community at upcoming PV in Focus events:

📍 Apr 18 – New York
📍 Apr 25 – Birmingham
📍 May 2 – Detroit, MI

Learn more and register: www.pvinfocus.com

🩸Today’s questions!

Swipe to see the answers and their explanations.

#Hematology #ClinicalHematology #Myelofibrosis #PolycythemiaVera #MyeloproliferativeNeoplasms #MPN #PostPVMF #BoneMarrowDisorders #Splenomegaly #Leucoerythroblastosis #HemeOnc #MedEd #HemeHub #ACVR1 #ALK2

𝗔 𝗯𝗲𝘁𝘁𝗲𝗿 𝘄𝗮𝘆 𝘁𝗼 𝗻𝗮𝘃𝗶𝗴𝗮𝘁𝗲 🚀

Today we’re introducing a new feature.

Chat → input
Dashboard → insight
Settings → control

Now all connected.

One flow. Finally simple ✨
More coming soon 👀

#MPN #MPNPatients #Hematology #Oncology #PolycythemiaVera #MyeloproliferativeNeoplasms

A patient from Cuba transformed complex #MPN biology into a powerful human story.
Living with polycythemia vera is challenging anywhere.
Support global patient education:
• Donate
• Share
• Join MPN World

#PolycythemiaVera #MPNCommunity #GlobalHealth #PatientAdvocacy

To close out Season 2 of our podcast, we reflect on the themes that shaped this season—from lived experiences and shared challenges to insights on #PolycythemiaVera care, connection, and advocacy.

Listen now: podcasts.apple.com/us/podcast/a...

We’re excited to kick off the first PV in Focus event of 2026 in Fort Lauderdale on 2/28!

PV in Focus brings people together for a day focused on education, shared experiences, and meaningful conversation around #PolycythemiaVera (PV).

Learn more: www.pvinfocus.com

NDA Submitted to FDA for Rusfertide for Polycythemia Vera | OncLive The FDA has received a new drug application seeking the approval of rusfertide for the treatment of adult patients with polycythemia vera.

NDA Submitted to FDA for Rusfertide for #PolycythemiaVera #oncology #hematology

www.onclive.com/view/nda-sub...

For patients with #PolycythemiaVera, #rusfertide provided durable, sustained hematocrit control that stayed below 43% and reduced #phlebotomy requirements up to 52 weeks, with 61.9% of patients remaining ineligible for phlebotomy between 0-52 weeks: https://ow.ly/KYiZ50XKVRT
#HemeSky #MedSky

#ASH25 Based on findings from the largest prospective analysis of #renal impairment in patients with #PolycythemiaVera (PV), a history of #thromboembolism, high-risk PV, and elevated LDH were found to be associated with rapid decline in #kidney function: https://ow.ly/AmqA50XExMH
#HemeSky #MedSky

Results from the phase II Shorespan-004 trial, to be presented at #ASH25, indicate that oral #bomedemstat effectively reduced hematocrit to less than 45% by week 36 in 45% of patients with previously treated #PolycythemiaVera: https://ow.ly/2bmS50XCMyM
#HemeSky #MedSky

At #SOHO2025, Asfand Yar Cheema of @clevelandclinic.bsky.social stopped by to share insights into the clinical outcomes of patients with #PolycythemiaVera or MDS treated with GLP-1 agonists.

Click here to watch the interview:

👉 buff.ly/KcqIbrj 👈

#MDSsm #MPNsm #HemOnc #BloodSky #HemeSky #MedSky

I remember the first time I saw trials available for the MPNs (rare blood cancers: #EssentialThrombocytopenia #PolycythemiaVera & #Myelofibrosis). Going from no available treatments to several has been life-saving, and new treatments were on the horizon. Now what? 🩸#Cancer

Rusfertide Shows Promising Efficacy and Safety in Treating Polycythemia Vera - Hematology Advisor Researchers sought to determine whether rusfertide would be a safe and effective treatment for patients with polycythemia vera.

Rusfertide shows promising efficacy and safety in the treatment of #polycythemiaVera. Presented at #SOHO2025.

https://bit.ly/46u5cVg

PV in Focus is almost here! If you or a loved one have #PolycythemiaVera (PV), join us to hear from speakers, gain tools, and connect with others.

• Sep 13 – Dallas, TX
• Oct 4 – Chicago, IL
• Oct 18 – Los Angeles, CA

Details & RSVP: PVInFocus.com

FDA Grants Breakthrough Therapy Designation to Rusfertide for Erythrocytosis in Polycythemia Vera Rusfertide earned an FDA breakthrough designation for polycythemia vera based on findings from the phase 3 VERIFY study.

FDA Grants Breakthrough Therapy Designation to Rusfertide for Erythrocytosis in #PolycythemiaVera #oncology

www.onclive.com/view/fda-gra...

If you or a loved one are living with #polycythemiavera (PV), join us for PV In Focus to meet others living with PV and hear from speakers on treatment options, self-advocacy & navigating PV and your mental health.
• Sept 13 – Dallas, TX
• Oct 4 – Chicago, IL
RSVP: PVInFocus.com

I've just made a donation to @bloodcanceruk.bsky.social

Lune Street #Darts Team do it again.
Me, Jack Puckrin, Shaun Matthews, Dave Wilkinson, Chris Rees, Si O’Connor, Si Temple, Lewis Coates, Ryan Butler, Kieran Mackay, Phil Anderson, Harrison Rees.
🙌🏽🎯
#PolycythemiaVera #LoveTheDarts

To our #PolycythemiaVera (PV) community: Join us for PV In Focus, a live patient and caregiver event on September 13th in Dallas, TX.

Learn about treatment options, self-advocacy, and navigating PV and your mental health.

Find details and RSVP today at PVInFocus.com

At #ASCO25, Andrew Kuykendall of @moffittnews.bsky.social‬ shared the rationale for investigating rusfertide in pts with #PolycythemiaVera requiring regular phlebotomies, and presented an update of the VERIFY trial.

Watch now!
🎥 buff.ly/jaRl96F

#MPNsm #CTSM #TrialUpdate @ascocancer.bsky.social‬

PV in Focus is right around the corner! If you or a loved one are living with #PolycythemiaVera (PV), join us on June 21st in Orlando, FL. Hear from speakers, gain tools, and connect with others.

Find the details and RSVP at PVInFocus.com.

A plenary discussion focused on #polycythemiavera #PV!

#VERIFY emphasizes quality of life. Recognizing that it’s not just about HCT or # of phlebotomies but How patients feel and the experience of living with the disease that make meaningful outcomes.

#ASCO2025

Conclusion slide by Dr. Andrew Kuykendall on VERIFY Rusfertide study for patients with PCV. Meaningful impacts on transfusion requirements and patient reported outcomes demonstrated in this pivotal study. #hematology #ASCO25 #polycythemiavera #mpnsm

To our #PolycythemiaVera (PV) community: Join us for PV In Focus, a live patient and caregiver event on June 21st in Orlando, FL.

Learn about treatment options, self-advocacy, and navigating PV and your mental health.

Find details and RSVP today at PVInFocus.com.

Cognitive fog in #polycythemiavera — what’s causing it? 

PV patients sometimes report memory lapses, trouble focusing, but why? Research points to low oxygen delivery, microvascular issues & chronic inflammation.  

We need answers. More research = better brain health.

Hepcidin Agents Set to Improve Polycythemia Vera Care Protagonist Therapeutics earlier this month reported positive results from its phase III VERIFY study of hepcidin mimetic rusfertide for th...

#Hepcidin agents set to improve #PolycythemiaVera care (blog): rnaitherapeutics.blogspot.com/2025/03/hepc...

$PTGX $SLN $IONS #rusfertide #divesiran #sapablursen

#PolycythemiaVera following $PTGX rusfertide p3 data release, $IONS finalizes global licensing deal with phase 2 TMPRSS6 ASO kd agent #sapablursen with Ono.

$280M upfront, i.e. more than $210M market cap of $SLN which has rival RNAi TMPRSS6 kd agent.

ir.ionis.com/news-release...

PV in Focus is right around the corner!

If you or a loved one are living with #PolycythemiaVera (PV), join us on April 5th in Boston, MA. Hear from speakers, gain tools, and connect with others.

Find the details and RSVP at PVInFocus.com.

#polycythemiavera #buddchiari The part I hate most about this stuff is the waiting. Am I muddling through the next 15-20 yrs or is it less than 5? I won’t find out until Tuesday, or more likely if the results are unclear - some point well after that.

Good news is that #rusfertide did not cause imbalance in cancer...as had been concern following earlier uncontrolled studies.

Turns out, it's the cytoreductive agents (often oral small mol) #polycythemiavera patients are taking. It kills me when people scaremonger about #CRISPR-related cancer risk.

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass., March 03, 2025--Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results f...

$ptgx reports p3 #polycythemiaVera results!

Hit on apparently all endpoints (incl patient-reported outcomes), but patient pop studied fairly well controlled already:

1.8 (pbo) vs 0.5 (#rusfertide) phlebotomies during weeks 0-32.

Ball now in $sln court.

finance.yahoo.com/news/protago...